Your browser doesn't support javascript.
Making Every Effort
Pharmaceutical Technology Europe ; 32(4):5, 2020.
Article in English | ProQuest Central | ID: covidwho-20243750
ABSTRACT
While the majority of the world is in isolation to try to slow the spread of the virus responsible for COVID19, companies and regulatory bodies in the bio/pharma industry are facing numerous challenges and committing significant efforts to support the development of novel therapeutics and monitor supply chains. Some notable drugs and vaccines for COVID-19 in development are * Messenger RNA vaccines, from CureVac and BioNTech, are in preclinical stages. * Remdesivir, from Gilead Sciences, originally developed to treat Ebola, is in Phase III clinical trials. * SNG001, from Synairgen Research, is an inhaled formulation of interferon-beta-1a that is entering Phase II clinical trials. * Chloroquine and hydroxychloroquine are currently being investigated in clinical trials and are being donated by various companies for evaluation. The emptying of the shelves can be attributed to the, as of yet unproven, link with the drug having efficacy in the treatment of COVID-19. [...]in this current climate, it is imperative that pertinent scientific information that can be of reassurance and informative be disseminated with due diligence and care.
Keywords
Search on Google
Collection: Databases of international organizations Database: ProQuest Central Type of study: Experimental Studies / Prognostic study Topics: Vaccines Language: English Journal: Pharmaceutical Technology Europe Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: ProQuest Central Type of study: Experimental Studies / Prognostic study Topics: Vaccines Language: English Journal: Pharmaceutical Technology Europe Year: 2020 Document Type: Article